The influence of the physical stress on the blood bnp level in patients with coronary artery disease
Keywords:
physical stress, brain natriuretic peptide (BNP), coronary artery disease (CAD)Abstract
Introduction: The coronary artery disease (CAD) results from the impaired balance between the left ventricle requirement for oxygen and possibilities of its supply, especially during physical stress. Left ventricle wall motion abnormalities are one of the reasons of BNP blood level increase. The aim of the study was to estimate the influence of the physical stress on the BNP blood level.
Material and methods: BNP blood level was determined in 109 patients with coronary artery disease, both at rest and stress, using the immumoradiometric assay.
Results: In patients with CAD the rest BNP blood concentration amounted to 46,51 ±69,28 Wm! while during the physical stress — 45,96 ±67,05 pghnt There were no statistically significant difference between these two values.
Conclusions: In patients with CAD physical stress does not cause the BNP blood level elevation. The influence ofphysical stress on the BNP blood level and its usefulness in early diagnostic of left ventricle ischaemia still need further investigations.
Downloads
References
Ganz P., Ganz W., Coronary blood flow and myocardial ischemia, z Braunwald E., Zipes D.P., Libby P., Heart disease. A textbook of cardiovascular medicine, W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Toronto, 2001.
Libby P. The vascular biology of atherosclerosis, z Braunwald E., Zipes D.P., Libby P., Heart disease. A textbook of cardiovascular medicine, W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Toronto, 2001.
Chrzanowski Ł., Peptydy natriuretyczne – nowe możliwości zastosowania w diagnostyce i leczeniu chorób układu krążenia, Pol Przeg Kardiol 2002, 4, 2, 171–173.
Gackowski A., Isnard R., Piwowarska W., Komajda M., Peptyd natriuretyczny typu B., Kardiol Pol. 2002, 56, 644.
Irzmański R., Rózalski S., Pawlicki L., Peptydy natriuretyczne w chorobach układu krążenia, Kardiol Pol 2000, 53, 44.
Kubler P., Banasiak W., Reczuch K., Ponikowski P., O BNP – nowym wskaźniku prognostycznym w ostrych zespołach wieńcowych, Kardiol Pol 2003, 58, 412.
Tylicki L., Manitius J., Rutkowski B., Zastoinowa niewydolność krążenia. Nerkowa regulacja wydalania sodu i wody, Kardiol Pol 1997, 47, 47.
Yoshimura M., Mizuno Y., Harada E., Nakayama M., Shimasaki Y., Ito T., Interaction on Metabolic Clearance Between A-Type and B-Type Natriuretic Peptides in Patients With Heart Failure, Metabolism 2000, 49, 9, 1228–1233.
Kyriakides Z.S., Markianos M., Michalis L., Antoniadis A., Nikolaou N.I., Kremastinos D.T., Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty, Clin Cardiol. 2000 Apr; 23(4): 285–8.
Sudoh T., Minamino N., Kangawa K., Matsuo H., A new natriuretic peptide in human brain, Nature 1988; 332: 78–81.
Cheung B.M.Y., Kumana C.R., Natriuretic peptidesrevelance in cardiac disease, JAMA 1998, 280, 1983–4.
Ruskiaho H., Leskinen H., Magga J., Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric-oxide and angiotensin II, J Mol Med 1997, 75, 876–85.
Stein B.C., Levin R.I., Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease, American Heart Journal, 1998, Vol 135, nr 5, part 1.
Wiese S., Breyer T., Dragu A., Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium. Influence of angiotensin II and diastolic fiber length, Circulation 2000, 102, 3074–9.
Cowie M.R., BNP: soon to become a routine measure in the care of patients with heart failure? Heart 2000, 83, 617018.
Arad M., Elazar E., Shotan A., Klein R., Rabinowitz B., Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure, Cardiology. 1996 Jan-Feb; 87(1):12–7.
Bay M., Kirk V., Parner J., Hassager C., Nielsen H., NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function, Heart 2003 Feb; 89(2):150–4.
Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A., Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study, Am J Med. 2004 Apr 15; 116(8):509–16.
Davidson N.C., Naas A.A., Hanson J.K., Kennedy N.S., Coutie W.J., Struthers A.D., Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction, Am J Cardiol, 1996 Apr 15; 77(10):828–31.
Celiński R., Cholewiński W., Stefaniak B., Tarkowska A., Relationship between plasma BNP levels and left ventricular diastolic function as measured by radionuclide ventriculography in patients with coronary artery disease, Nucl Med Rev 2004, 2, 123–128.
Celiński R., Grzywa-Celińska A., Cholewiński W., Stefaniak B., Tarkowska A., Ocena zależności między stężeniem mózgowego peptydu natriuretycznego we krwi a funkcją skurczową komory lewej w chorobie niedokrwiennej serca, Pol Merk Lek 2005, XVIII, 105, 291.
Celiński R., Grzywa-Celińska A., Cholewiński W., Stefaniak B., Tarkowska A., Poziom BNP we krwi a perfuzja i funkcja komory lewej w przypadkach choroby niedokrwiennej serca, Problemy Medycyny Nuklearnej 2004; 18(36): 143–152.
Barletta G., Stefani L., Del Bene R., Fronzaroli C., Vecchiarino S., Lazzeri C., Effects of exercise on natriuretic peptides and cardiac function in man, Int J Cardiol. 1998 Aug; 65(3):217–25.
Jonsdottir S., Andersen K.K., Sigurosson A.F., Sigurosson S.B., The effect of physical training in chronic heart failure, Eur J Heart Fail, 2006 Jan; 8(1): 97–101.
Kruger S., Graf J., Merx M.W., Stickel T., Kunz D., Hanrath P., Janssens U., Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure, Int J Cardiol, 2004 May; 95(1): 49–54.
Kato M., Kinugawa T., Ogino K., Endo A., Osaki S., Igawa O., Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure, J Intern Med, 2000 Oct; 248(4): 309–15.
McNairy M., Gardetto N., Clopton P., Garcia A., Krishnaswamy P., Kazanegra R.., Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide, Am Heart J, 2002 Mar; 143(3): 406–11.
Mottram P.M., Leano R., Marwick T.H., Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function, Am J Cardiol, 2003 Dec 15; 92(12): 1434–8.
Asada J., Tsuji H., Iwasaka T., Thomas J.D., Lauer M.S., Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia, Am J Cardiol. 2004 Mar 15; 93(6):702–4.
Bentzen H., Pedersen R.S., Nyvad O., Pedersen E.B., Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure, Int J Cardiol. 2004 Feb; 93(2–3):121–30.
Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A., B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study, Circulation, 2003 Dec 16; 108(24): 2987–92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2007 Medical Journal of the Rzeszow University
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
